AWHL Aspira Women's Health (AWHL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000926617
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about AWHL
Insiders, 180 days
+$100.0K net bought
1 buyer
Aspira Women's Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Aspira Women's Health Inc. insiders bought a net $100.0K of stock across 4 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 17, 2025.
- The trade is 5.5% of the 4,046,051 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider SCHULER JACK W bought about $100.0K of AWHL on Jun 5, 2026.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 29.1% of the 3,823,829 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Insider SCHULER JACK W bought about $500.0K of AWHL on Sep 17, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.9% of the 566,393 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Fraser John D bought about $7.4K of AWHL on Sep 17, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.8% of the 374,906 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director cohen Jeffrey k bought about $25.0K of AWHL on Sep 17, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$100.0K over 180 days
+$100.0K of it by a 10%+ holder
more than 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+0.4% year over year
below 53% of Pharma & Biotech
Margin
-138.7% net margin
below 61% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AWHL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-67.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AWHL: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in AWHL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AWHL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $100.0K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
AWHL financials
Revenue growth
+0.4%
XBRL, annual
Net margin
-138.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AWHL
| FY Dec 2025 | $9.2M |
| FY Dec 2024 | $9.2M |
| FY Dec 2023 | $87.0M |
| FY Dec 2022 | $8.2M |
| FY Dec 2021 | $6.8M |
| Jun 2026 | $2.0M |
| Mar 2026 | $2.0M |
| Dec 2025 | $2.2M |
| Sep 2025 | $2.3M |
| Jun 2025 | $2.4M |
| Mar 2025 | $2.3M |
| Dec 2024 | $2.3M |
| Sep 2024 | $2.3M |
At each fiscal year end
Single quarter
Net margin, TTM
+32.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AWHL
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -365.2% |
| FY Dec 2021 | -464.8% |
| Jun 2026 | -118.3% |
| Mar 2026 | +34.4% |
| Dec 2025 | +421.8% |
| Sep 2025 | -212.2% |
| Jun 2025 | -110.9% |
| Mar 2025 | -81.3% |
| Dec 2024 | +497.8% |
| Sep 2024 | -157.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$12.2M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$31.3M |
| FY Dec 2021 | -$27.6M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$2.0M |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$1.0M |
| Sep 2024 | -$2.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.39x |
| FY Dec 2021 | 0.10x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.93x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AWHL
| FY Dec 2025 | -5.50x |
| FY Dec 2024 | -8.04x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -11.43x |
| FY Dec 2021 | -9.39x |
| Jun 2026 | -3.93x |
| Mar 2026 | -3.52x |
| Dec 2025 | -5.50x |
| Sep 2025 | -4.55x |
| Jun 2025 | -6.31x |
| Mar 2025 | -7.44x |
| Dec 2024 | -8.04x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.7% |
| FY Dec 2022 | -160.9% |
| FY Dec 2021 | -158.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+59.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AWHL
| FY Dec 2025 | -0.2% |
| FY Dec 2024 | -0.2% |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -102.3% |
| FY Dec 2021 | -104.4% |
| Jun 2026 | +59.0% |
| Mar 2026 | +42.6% |
| Dec 2025 | -0.2% |
| Sep 2025 | +37.9% |
| Jun 2025 | +69.6% |
| Mar 2025 | +39.8% |
| Dec 2024 | -0.2% |
| Sep 2024 | +28.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed AWHL
| FY Dec 2025 | -785.8% |
| FY Dec 2024 | -2,792% |
| FY Dec 2023 | -290.3% |
| FY Dec 2022 | -138.1% |
| FY Dec 2021 | -139.2% |
| Jun 2026 | n/a |
| Mar 2026 | -568.7% |
| Dec 2025 | -785.8% |
| Sep 2025 | -841.8% |
| Jun 2025 | -2,814% |
| Mar 2025 | -617.5% |
| Dec 2024 | -2,792% |
| Sep 2024 | -1,216% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$7.2M
market value at close 2026-10-27 on 2026-08-12 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AWHL
| FY Dec 2025 | $26.4M |
| FY Dec 2024 | $11.6M |
| FY Dec 2023 | $41.2M |
| FY Dec 2022 | $605.4M |
| FY Dec 2021 | $2.9B |
| Jun 2026 | $18.5M |
| Mar 2026 | $15.5M |
| Dec 2025 | $26.4M |
| Sep 2025 | $15.0M |
| Jun 2025 | $4.4M |
| Mar 2025 | $816.8K |
| Dec 2024 | $11.6M |
| Sep 2024 | $12.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | -102.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -5.1% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -34.9% |
| Jun 2025 | -194.9% |
| Mar 2025 | -404.0% |
| Dec 2024 | -102.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AWHL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.2M | $9.2M | $87.0M | $8.2M |
| Gross profit | $5.9M | $5.5M | $5.3M | $4.3M |
| Operating income | -$7.9M | -$16.3M | -$18.9M | -$31.1M |
| Net income | -$12.8K | -$13.1K | -$17.0K | -$29.9M |
| EPS (diluted) | -0.37 | -0.93 | n/a | -3.85 |
| Operating cash flow | -$7.0M | -$12.1M | -$15.9M | -$31.1M |
| Cash | $1.8M | $1.8M | $2.6M | $13.3M |
| Long-term debt | $1.0M | $1.3M | $1.4M | $2.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
AWHL Stock Sonar score 4/7 axes
Find similar shapesCompareAWHL ranks highest on risk and compliance (82nd percentile) and insider conviction (66th), and lowest on financial health (34th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AWHL filings, in plain words
Are Aspira Women's Health insiders buying or selling AWHL?
In the 180 days to 2026-10-28, Aspira Women's Health insiders were net buyers, a net $100.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Aspira Women's Health insiders were net buyers of AWHL, a net $100.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $100.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
